Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Todd Watanabe Sells 37,349 Shares

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insider Todd Watanabe sold 37,349 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $25.18, for a total transaction of $940,447.82. Following the sale, the insider owned 785,957 shares of the company’s stock, valued at $19,790,397.26. This trade represents a 4.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Todd Watanabe also recently made the following trade(s):

• On Monday, February 2nd, Todd Watanabe sold 19,833 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $25.50, for a total value of $505,741.50.

Arcutis Biotherapeutics Price Performance

Shares of NASDAQ:ARQT opened at $23.60 on Wednesday. The company has a market cap of $2.93 billion, a price-to-earnings ratio of -168.56 and a beta of 1.66. The business has a 50 day moving average price of $27.02 and a 200 day moving average price of $24.03. The company has a quick ratio of 2.99, a current ratio of 3.17 and a debt-to-equity ratio of 0.57. Arcutis Biotherapeutics, Inc. has a twelve month low of $11.86 and a twelve month high of $31.77.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.10. Arcutis Biotherapeutics had a negative return on equity of 10.26% and a negative net margin of 4.29%.The company had revenue of $129.50 million during the quarter, compared to analyst estimates of $110.79 million. Research analysts predict that Arcutis Biotherapeutics, Inc. will post -1.33 earnings per share for the current year.

Arcutis Biotherapeutics News Roundup

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Arcutis announced first participant enrollment in a Phase 1a/1b study of ARQ-234 (a CD200R agonist) to evaluate safety/tolerability in healthy volunteers and adults with moderate–severe atopic dermatitis — a clear pipeline positive that supports long-term growth potential. ARQ-234 trial enrollment
• Neutral Sentiment: Broker action: Mizuho lowered its price target from $37 to $35 but kept an “Outperform” rating — a modest near-term negative signal (slightly lower PT) but still positive conviction from the analyst. Mizuho note
• Neutral Sentiment: Fund reporting: Baron Health Care Fund published Q4 2025 activity (fund filings sometimes move small- and mid-cap biotechs), but the feed doesn’t specify a material position change in ARQT. Baron fund activity
• Neutral Sentiment: Short-interest data in the feed is inconsistent/erroneous (reports show 0 shares / NaN changes), so it provides no actionable signal to explain today’s move. Investors should treat those figures as unreliable until clarified by exchange data.
• Negative Sentiment: Insider selling: multiple company insiders sold shares on Feb 27–Mar 2 (including Todd Watanabe, Masaru Matsuda, Patrick Burnett, CFO Latha Vairavan and others). The aggregated sales total ~62,000 shares across named insiders (largest single sale ~37,349 shares by Watanabe). Insider sales can be interpreted as near-term negative sentiment or simple liquidity diversification — but the market often reacts negatively to clustered insider dispositions. Representative SEC filings: Todd Watanabe sale Watanabe Form 4, Masaru Matsuda filings Matsuda Form 4

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Focus Partners Wealth boosted its holdings in Arcutis Biotherapeutics by 0.8% during the third quarter. Focus Partners Wealth now owns 65,196 shares of the company’s stock valued at $1,237,000 after purchasing an additional 490 shares in the last quarter. Arizona State Retirement System boosted its stake in Arcutis Biotherapeutics by 1.8% in the 3rd quarter. Arizona State Retirement System now owns 31,685 shares of the company’s stock valued at $597,000 after buying an additional 568 shares in the last quarter. Schroder Investment Management Group grew its position in Arcutis Biotherapeutics by 1.1% in the fourth quarter. Schroder Investment Management Group now owns 57,136 shares of the company’s stock valued at $1,604,000 after acquiring an additional 594 shares during the period. AlphaQuest LLC grew its position in Arcutis Biotherapeutics by 5.7% in the third quarter. AlphaQuest LLC now owns 12,603 shares of the company’s stock valued at $238,000 after acquiring an additional 682 shares during the period. Finally, EverSource Wealth Advisors LLC raised its stake in Arcutis Biotherapeutics by 124.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company’s stock worth $37,000 after acquiring an additional 698 shares in the last quarter.

Wall Street Analysts Forecast Growth

ARQT has been the topic of several research analyst reports. TD Cowen raised their price target on shares of Arcutis Biotherapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research note on Monday, December 29th. Zacks Research downgraded Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 29th. HC Wainwright boosted their price target on Arcutis Biotherapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Finally, Needham & Company LLC raised their price objective on Arcutis Biotherapeutics from $31.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $31.86.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.